Post-marketing surveillance in the published medical and grey literature for percutaneous transluminal coronary angioplasty catheters: a systematic review by Julie Polisena et al.
Polisena et al. Systematic Reviews 2013, 2:94
http://www.systematicreviewsjournal.com/content/2/1/94RESEARCH Open AccessPost-marketing surveillance in the published
medical and grey literature for percutaneous
transluminal coronary angioplasty catheters: a
systematic review
Julie Polisena1,2*, Alan J Forster2,3,4,5,6, Karen Cimon1 and Danielle Rabb1Abstract
Background: Post-marketing surveillance (PMS) may identify rare serious incidents or adverse events due to the
long-term use of a medical device, which was not captured in the pre-market process. Percutaneous transluminal
coronary angioplasty (PTCA) is a non-surgical procedure that uses a balloon-tipped catheter to enlarge a narrowed
artery. In 2011, 1,942 adverse event reports related to the use of PTCA catheters were submitted to the FDA by the
manufacturers, an increase from the 883 reported in 2008. The primary research objective is to conduct a
systematic review of the published and grey literature published between 2007 and 2012 for the frequency of
incidents, adverse events and malfunctions associated with the use of PTCA catheters in patients with coronary
artery disease (CAD). Grey literature has not been commercially published.
Methods: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and PubMed for
medical literature on PMS for PTCA catheters in patients with CAD published between January 2007 and July 2012.
We also searched the grey literature.
Results: This review included 11 studies. The in-hospital adverse events reported were individual cases of
myocardial infarction and hematoma. In studies of patients with coronary perforation, more patients with balloon
angioplasty were identified compared with patients who required stenting.
Conclusions: Our systematic review illustrates that the volume and quality of PMS studies associated with the use
of PTCA catheters in patients with CAD are low in the published and grey literature, and may not be useful sources
of information for decisions on safety. In most studies, the objectives were not to monitor the long-term safety of
the use of PTCA catheters in clinical practice. Future studies can explore the strengths and limitations of PMS
databases administered by regulatory authorities.
Keywords: Post-marketing surveillance, Medical device, Incident, Adverse event, MalfunctionBackground
The US Food and Drug Administration (FDA) defines a
medical device as an instrument used to diagnose, treat
or prevent a disease or abnormal physical condition
without any chemical action in the body [1]. The med-
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reproduction in any medium, provided the orBetween 2004 and 2009, the sales of medical devices in-
creased by 56%, while pharmaceutical sales increased by
38% during the same period [2]. Excluding diagnostics,
the medical device industry is a USD 200 billion busi-
ness worldwide, with projected sales of USD 95 billion
in 2010 in the US alone [2].
Unlike drug therapies, the approval processes for med-
ical devices typically do not require clinical effectiveness
and safety data derived from a randomized clinical trial
(RCT) [3], even for FDA class III medical devices, which
have the highest risk for patients. Manufacturers mustl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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standards for sample size, design or follow-up period, as
there are for medications [4,5]. Thousands of medical
device applications are submitted each year in the US.
However, fewer than 100 were considered to be high-risk
devices and went through a pre-market approval (PMA)
process. Instead, most applications undergo a 510(k), a
pre-market submission required by the FDA, where man-
ufacturers claim that their device is as safe and effective as
the comparator device available on the market. In these
studies, measures of safety and effectiveness are not
mandatory [3]. PMA is the strictest submission process
and the FDA requires that the submission contains valid
scientific evidence to ensure the safety and effectiveness of
the medical device during its intended use [6]. Equivalent
clinical evidence, therefore, would unlikely be available
across all medical devices, rendering product comparisons
nearly impossible [7].
Post-marketing surveillance (PMS) and epidemiology
programs are complementary to the pre-market process
since they may identify rare serious adverse events due
to long-term use of the medical device not captured
previously [4,8]. PMS collects data from the monitoring
and assessment of adverse reactions to marketed health
products, as well as standard market intervention and
communication procedures, and associated policy devel-
opment and business transformation activities [9]. Chal-
lenges associated with PMS studies include finding
sources with relevant medical device data and identifying
a patient population that had been exposed to a specific
medical device [10]. It is possible that device-related ad-
verse events are underreported since manufacturers are
not usually obliged to search for device malfunctions ac-
tively [11]. Further, there may be a disincentive to report
adverse events or device malfunctions if health-care
providers use them in patient populations not originally
approved by the regulatory authority [11,12].
Given the above limitations in the regulatory require-
ments for monitoring the safety of medical devices, it is
possible that there are significant deficiencies in their
safety. While this might be true for all devices, we have
decided to focus specifically on cardiovascular devices.
The volume, complexity and costs of cardiovascular de-
vices are on the rise [11,12]. For example, the prevalence
of coronary artery disease (CAD) in 2005 was 16 million
people in the US, and the estimated direct and indirect
cost of CAD for 2008 was USD 156.4 billion [13]. Percu-
taneous transluminal coronary angioplasty (PTCA) is a
non-surgical procedure, which uses a balloon-tipped
catheter to enlarge a narrowed artery as an alternative to
open-heart surgery [14]. The PTCA catheter was ap-
proved by the FDA in 1980. In 2010, the FDA reclassi-
fied standard PTCA catheters from class III to class II
(that is, lower risk) when used for balloon dilation totreat narrowed or blocked arteries in patients with cor-
onary ischemia. To date, 33 catheters made by 10 manu-
facturers have been approved, including two devices in
2010 and seven devices in 2011 [15].
In 2011, 1,942 adverse event reports related to the use
of PTCA catheters were submitted to the FDA by the
manufacturers, an increase from the 883 reported in
2008 [15]. It is unclear if the rise in the number of ad-
verse event reports from 2008 to 2011 was related to re-
classification of the device from a class III to II risk level
(with a less stringent market approval process) or whether
a greater number of PTCA catheters were implanted in
patients with CAD during the time period. The patient
outcomes for 1,662 adverse events reported in 2011
remain unknown. In 2008, 26 adverse event outcomes
were reported versus 50 in 2011, and the most frequent
device malfunction reported was material rupture. Be-
tween 2009 and 2010, there were two class 1 recalls of
PTCAs, POWERSAIL® Coronary Dilation Catheters and
AngioSculpt PTCA, due to device malfunctions that could
lead to serious adverse events, including air embolism,
myocardial infarction (MI) and death [16,17]. Class 1 re-
calls are the most serious type of recall since they may in-
volve serious injury to or death of the patient [16].
The availability of PMS studies on adverse events and
malfunctions for PTCA catheters in patients with CAD
in the published medical literature is unknown. In
addition, the various methods adopted to monitor the
safety of this device following its implementation in
clinical settings remain elusive. By performing a system-
atic review of the literature to identify safety problems
associated with the device, we may be able to determine
whether the published medical literature is a useful
source of information to estimate the safety of PTCA
catheters. If we find useful information, then this ap-
proach could be adapted to monitor the safety of other
devices.
Objective
The primary research objective is to review systematic-
ally the medical and grey literature, published between
2007 and 2012, for post-marketing surveillance studies
on the frequency of incidents and malfunctions associ-
ated with the use of PTCA catheters in clinical practice
among patients with CAD.
Methods
Literature search strategy
We identified the published literature by searching the
following bibliographic databases: MEDLINE (from 1946)
with in-process records and daily updates via Ovid,
EMBASE (from 1980) via Ovid, the Cochrane Central
Register of Controlled Trials (2012, Issue 1) via Ovid and
PubMed. The search strategy consisted of both controlled
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MeSH (medical subject headings), and keywords. The
main search concepts were percutaneous transluminal
coronary angioplasty, heart catheterization and cutting or
scoring catheters combined with equipment safety and
failure, adverse events, post-marketing surveillance, med-
ical device recalls and withdrawals. The search strategy is
given in Additional file 1: Table S1. We limited the search
to English and French language documents published be-
tween 1 January 2007 and 16 July 2012 to reflect the po-
tential impact of the reclassification of PTCA catheters
from a class III to class II risk level by the FDA on patient
safety. We identified grey literature (literature that is not
commercially published) by searching relevant sections of
the Grey Matters checklist [18].
Selection criteria
The selection criteria include RCTs and non-randomized
studies, such as cohort and case–control studies, case
series and reports, that presented incidents, adverse
events, procedure complications or device malfunctions
related to the use of PTCA catheters among adult and
paediatric populations. Two reviewers (JP and KC) se-
lected the final articles for inclusion based on an examin-
ation of the full publications. Any disagreements between
the reviewers were discussed until a consensus was
reached. For our systematic review, incidents were defined
as events or circumstances that could have or did lead to
unintended and/or unnecessary harm to a person, and/or
a complaint, loss or damage; and adverse events were de-
fined as an unintended injury caused by medical manage-
ment rather than by a disease process [19].
Conference abstracts, letters and editorials were ex-
cluded. In addition, studies conducted to demonstrate
the effectiveness and safety of the devices for market ap-
proval were not included in this systematic review.
Article selection
Two individuals (JP, KC) independently reviewed the ti-
tles and abstracts of search results and selected articles
for inclusion based on the eligibility criteria. Rather than
resolving selection differences, all those selected by at
least one reviewer were retrieved since ultimate judg-
ment about inclusion must often be reserved until the
full text is examined. If more than one publication de-
scribed a single study and each presented the same data,
the most recent was included. Both reviewers compared
findings and resolved differences through discussion,
after which one study for each eligible instance was cap-
tured for further analysis.
Data extraction
One reviewer (JP) conducted the data abstraction for all
included studies using pre-specified extraction forms,and another reviewer (KC) verified the accuracy of the
data extracted from all included reports. Any disagree-
ments between the reviewers were discussed until a con-
sensus was reached.Quality assessment of included studies
Two reviewers (JP and KC) critically appraised independ-
ently the internal validity of the included studies using
checklist tools for RCTs and cohort and case–control stud-
ies available on the Scottish Intercollegiate Guidelines Net-
work website. Separate methodology checklists by study
design were used to assess the internal validity and overall
assessment of the study, including the generalizability.
Each tool addresses how well a study meets the different
components of the study design that may impact the study
findings and conclusions [20].Data analysis and synthesis
A formal meta-analysis was not performed since the aim
of this systematic review is to identify and present the
literature on adverse events and device malfunctions for
PTCA catheters reported in PMS studies, rather than to
test a hypothesis. Instead, the study design, medical de-
vice, patient population, health-care setting, interven-
tions, adverse events and device malfunctions measured
in each selected study were reviewed and described
individually.Results
Quantity of research available
The literature search identified 5,942 citations. Of these,
the full text of 144 potentially relevant articles was re-
trieved for further review. For this review, 11 studies
were selected for inclusion. Studies were excluded if they
included inappropriate study participants, measured an
inappropriate device, such as guidewires, guiding cathe-
ters and bare-metal or drug-eluting stents, did not spe-
cify the devices employed during the percuntaneous
coronary intervention (PCI) (also known as coronary
angioplasty), measured irrelevant outcomes, or limited
the findings to long-term clinical outcomes. The Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flowchart in Figure 1 outlines
the study selection process.Study characteristics
Four studies were conducted in Germany [21-24], two in
Italy [25,26], and one each in Israel [27], Taiwan [28],
the US [29] and Japan [30]. One study was performed in
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Figure 1 PRISMA flowchart.
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Three studies were non-blinded randomized trials
[22,23,25]. A single-arm prospective cohort study design
was used in three studies [21,28,29] and one study was a
three-arm prospective cohort in design [24]. Three
studies were retrospective cases series [31], one was a
single-arm retrospective cohort [30], one a three-arm
retrospective cohort [26] and one a case–control study
[27]. Four studies were multi-centred [21-23,29]. The
two- or three-armed studies assessed the comparative
effectiveness of PTCA catheters with comparable de-
vices or procedures. The one-armed studies aimed to
measure the rates of success or complications for the
patient with the use of the device.
Patient population
Two studies included populations with coronary perfora-
tions [28,31] and two studies included patients with re-
stenosis [22,26]. Patients with coronary total obstruction
lesions were selected in another two studies [22,26], and
patients with stable or unstable angina were included intwo studies [23,25]. Two studies encompassed patients
with single- or multi-vessel CAD [24,29], and the mor-
bidities of a patient population undergoing PCI was not
available in one study [27]. Sample sizes ranged from 21
[28] to 996 [24].
Intervention and comparators
In most studies, patients were treated with aspirin
[21,22,25,29,31], thienopyridine [31], clopidogrel [21,22,
25,29], heparin [22,28,31] or dual antiplatelet therapy
and procedural anticoagulation [29]. Guidewires and
guiding catheters were used in four studies as part of the
procedure [21,27,28,30]. Two studies incorporated stent
implantation in the study population [28,31], and one
study used intracoronary compliant, non-compliant or
cutting balloons [31]. A balloon’s compliance refers to its
expandability: compliant balloons are flexible and non-
compliant balloons are considered to be inflexible [32].
Balloon catheters in the studies were the Stingray balloon
catheter [21], Ryujin® [30], Lacross® [30], Maverick® [30],
PEGASO™ by SORIN Biomedica [23] and balloon
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by an exchange catheter
(CrossBoss™ Catheter, BridgePoint






Balloon dilation was conducted
with increasing sizes, and a stent
of an appropriate size was
implanted. A balloon-to-artery
ratio of 1.1 with inflation
pressures of 12 to 16 atm was
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No penetrations external to
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BridgePoint devices.
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Failure of Stingray balloon
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Failure of Stingray balloon
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of balloon ruptures or failure
of delivery
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Table 1 Study characteristics (Continued)
Balloon length, number of
catheters and number of
inflations used during procedures
were up to investigators’
discretion.
Cortese, 2010 [25] Single-centre
randomized trial
60 adult patients with
stable or unstable angina
and clinical indication for
PCI of at least one small
coronary artery
(≤2.75 mm)
All patients received aspirin
(either 100 mg/day for at least
three days prior or pre-PCI 300
mg intravenous bolus), and
clopidogrel (300 or 600 mg as a
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Group 1: 57 patients with CP Equipment causing CP:
Israel January 2001 to
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131 patients for the
treatment of coronary in-
stent restenosis
All patients were treated with
250 mg of aspirin intravenously,
heparin as an initial bolus of 70
to 200 U/kg body weight
adjusted according to the
activated clotting time with a
target of 200 to 250 seconds.
One day before the procedure, a
loading dose of 300 mg of
clopidogrel was administered or
600 mg before the intervention.
All patients were assessed based
on angiographic inclusion and
exclusion criteria.
Success rate with crossing
the lesion:
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Table 1 Study characteristics (Continued)
Germany January 2006 to
December 2006
Group 1: 65 patients in DES
group (Taxus)
Balloon catheter: 65/65; 100%
Source of funding:
industry
Group 2: 66 patients in coated-
balloon catheter group (SeQuent
Please)
DES: 61/66; 92.4%













myocardial infarction, or new
revascularization occurred
Italy 18 months 39 patients were treated with
homo-DES implantation (patients




26 patients were treated with
hetero-DES implantation
(patients eluted with different
drug used in previous DES
implantation)
Chua, 2008 [28] Single-arm
retrospective
cohort study
21 patients with CAD
who underwent PCI and
experienced procedure-
related CP
All patients received intravenous
heparin (100 units/kg) at the
beginning of the procedure.
Occurrence of CP:
Taiwan October 1992 to
December 2006
All patients were treated with
percutaneous transfemoral or












Saito, 2008 [30] Single-arm
retrospective
cohort study
45 patients treated with
PCI for CTO lesions of
coronary arteries
Two 7-French guiding catheters
were used in all patients.
Microcatheters were inserted into
targeted collateral artery with
support from guidewires.
One case of transient
ischemia in target region
caused by a false spasm of
tortuous epicardial collateral
artery by guidewire and
balloon catheter insertion
was reported. No residual
ischemia was found.
Japan January 2006 to
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into target artery, balloon
catheters (Ryujin® -OTW 1.25 mm
× 10 mm, Terumo, Lacross® 1.30
mm × 10 mm, Goodman, Japan
or Maverick® -OTW 1.50 mm ×
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successful crossing of collateral
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ischaemia due to one or
two de novo lesions in
coronary arteries of less
than 2.8 mm in diameter
Group 1: 106 patients were
treated with standard angioplasty
balloon (PEGASO™, SORIN
Biomedica, Italy) of 2.5 mm
diameter at 6 atm.
In-hospital MACE (MI):
Six months Group 2: 116 patients received a
2.5-mm carbon-coated stent
(SYNCRO™, SORIN Biomedica
Italy) available in 9, 12, 15 and 19
mm of length with or without








Hematoma at puncture site:
POBA: 2/106; 1.9%
Stent: 0/116; 0%
Aneurysm at puncture site:
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CAD coronary artery disease, CP coronary artery perforation, CS coronary stent, CTO coronary total occlusion, CTR clinical trial registration, DES drug eluting stent,
ISR in-stent restenosis, MACE major adverse cardiac event, MI myocardial infarction, NR not reported, NSTEMI non-ST elevation myocardial infarction, PCI
percutaneous coronary intervention, POBA plain old balloon angioplasty, PTCA percutaneous transluminal coronary angioplasty, TVR target vessel revascularization.
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paclitaxel-coated balloon catheters mad by Eurocar [29]
and coated-balloon catheters by SeQuent Please [22] were
also studied. Two studies compared the effectiveness and
safety of drug-coated balloon catheters with a drug eluting
stent (DES) [22,25], two studies compared the outcomes
in patients who were treated with standard balloon angio-
plasty versus those with DES implantation [23,26]. One
prospective study compared the long-term prognosis fol-
lowing the PTCA procedure with coronary stenting andCABG [24]. Details of the interventions were not available
in one study [27].
Quality assessment
A quality assessment of single-arm studies was not
performed since these study designs were descriptive,
provided limited information and did not test any hy-
potheses. The methodological quality of six studies was
reviewed [22-27]. In the case–control study, the inter-
ventional cardiologist, who determined the severity of
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the clinical outcomes to reduce the risk of information
bias [27]. Although the authors conducted a multiple
logistic regression analysis to identify the predictors for
coronary perforation, the selection of variables was not
discussed, and it was uncertain if potential confounders
were adjusted for in the study [27]. An assessment of the
retrospective cohort study found that it was unclear if
the investigators were blinded to the outcomes or if po-
tential confounders were considered in the study design
and analysis [26]. Moreover, the authors did acknow-
ledge that failure to randomize the patient populations
may have influenced the study findings [26]. Three ran-
domized trials were not blinded, which increases the risk
of information bias for the study outcomes [22,23,25]. In
one trial, the two study investigators were blinded to the
patient treatment allocation [25]. Two studies did not dis-
cuss the percentage or number of patients who dropped
out or were lost to follow-up before the study ended
[22,23], but three out of 57 patients were lost to follow-up
in the PICCOLETO study [25]. In addition, intention-to-
treat (ITT) analysis was mentioned in two trials, but it was
not described [22,25]. One study did not indicate if the
analyses were done on an ITT basis, so it is difficult to de-
termine if the participants remained randomized through-
out the study [23]. Two trials had multiple study centres
where it was not possible to determine if the outcomes
were comparable across all sites [22,23]. In one prospect-
ive cohort study, several baseline demographic and clinical
characteristics differed among the patient groups, which
may be associated with the measured outcomes [24]. For
example, patients who received CABG surgery were older,
were more likely to be male or diabetic, have a previous
history of MI or increased disease severity versus patients
with PTCA [24]. Patients with coronary stents also were
more likely to have a positive MI history, a three-vessel
CAD, and left anterior descending or stenosis greater than
50% in the right coronary artery compared with patients
with PTCA [24].
Data analysis and synthesis
Adverse events
No in-hospital adverse events, such as death, acute stent
thrombosis, myocardial infarction or revascularization,
were reported to have occurred due to a complication of
balloon angioplasty [26]. One case of in-hospital myocar-
dial infarction was reported in one study for a patient with
angina, who was treated with a standard angioplasty bal-
loon (1/106; 0.9%) [23]. Furthermore, two patients suffered
from hematoma at a puncture site (2/106; 1.9%), and from
contrast reaction (2/106; 1.9%). In the same study, no in-
hospital major acute coronary events were found with pa-
tients who were treated with carbon-coated stents (0/116;
0%). One patient, however, experienced an aneurysm at apuncture site with the use of a stent [23]. In a single-arm
study, the frequency of coronary perforation was the
highest with the application of coronary balloon angio-
plasty (13/21; 61.9%) compared with guidewire manipula-
tion (5/21; 20.8%) and coronary stenting (3/21; 14.3%)
[28]. Coronary perforation is a rare but sometimes fatal
complication associated with PCI [33]. Another single-
arm study, which included only patients with a coronary
perforation, found that there were more patients with a
perforation with the use of intracoronary compliant bal-
loon catheters (15/56; 26.8%) versus intracoronary non-
compliant balloon catheters (13/56; 23.2%) and cutting
balloons (4/56; 7.1%); however, there was no data on the
total number of patients using each type of balloon [28].
Among patients who experienced a grade III coronary per-
foration, Shimony et al. found that the use of wires (30/57;
53%) was associated with the greatest frequency of coron-
ary perforation compared with balloon catheters (15/57;
26%) and stents (12/57; 21%) [27]. This study only in-
cluded patients with perforations, therefore, no data on
the number of patients treated with each device was
recorded. Long-term mortality was 22.1% (53/240) among
patients who underwent CABG versus those with PTCA
(19.9%; 95/478) and those with coronary stents (16.2%; 45/
278) [24]. A greater proportion of patients with PTCA
experienced major adverse cardiac events (66.3%; 317/
478) versus those with coronary stents (49.6%; 138/278),
followed by CABG (33.3%; 80/240) [24]. Conclusions re-
garding differences in rates in this study are impossible be-
cause of a lack of randomization.
Procedure complications
There were no procedure complications associated with
balloon or balloon-coated catheters reported in two stud-
ies [22,29]. Procedural success occurred in 96.4% (27/28)
of cases with paclitaxel-coated balloon catheters versus
100% (29/29) with Taxus stents [25]. One study reported
occurrences of failure with the use of Stringray balloons.
For instance, failure to advance into the proper position
(2/14; 14.3%), to advance after a re-entry attempt (3/10;
30%) and a re-entry puncture as a result of loss of distal
contrast filling (2/10; 20%) were reported [21].
Device malfunctions
One study indicated that there were no balloon ruptures
or failure of delivery with the application of a 1.25-mm-
diameter angioplasty balloon among patients with CAD
[29]. Occurrences of device malfunctions were not men-
tioned in the remaining studies.
Discussion
Summary of evidence
Our systematic review included 11 studies that reported
in-hospital adverse events, procedure complications and
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patients with CAD. In-hospital adverse events reported
were individual cases of myocardial infarction and
hematoma. In studies of patients with coronary perfor-
ation, more patients with balloon angioplasty were iden-
tified compared with patients who required stenting;
however, these studies neglected to evaluate the at-risk
population. As more patients undergo angioplasty than
stenting, then the comparative risk is uncertain. In these
studies [27,28], there were conflicting results regarding
balloon angioplasty and guidewires. Since the interven-
tions were not described in the studies, and study design
and sample differed, it was difficult to determine the
discrepancies in the findings between the studies. Pro-
cedure complications and device malfunctions were
reported rarely and when they were they occurred infre-
quently. One review found that balloon-only PTCA was
associated with a greater risk of angiographic restenosis
versus bare-metal and drug-eluting stents [34]. Long-
term adverse events reported in one study included
mortality and MACE [24].
Our study highlights that a systematic review of the
published and grey literature as a method to identify po-
tential safety issues or ruptures associated with the use
of PTCA catheters in patients with CAD is inadequate
compared with the number of adverse reports submitted
to the FDA in 2011 (1,942 adverse events in 2011). In
most studies, the objectives were not to monitor the
long-term safety aspects on the use of PTCA catheters
in clinical practice. For instance, many studies ranged
from 6 to 18 months in length, and their study popula-
tions were less than 250 patients. Even for short-term
studies, the reporting of procedure- and device-related
adverse events was inadequate. For example, several
studies did not identify a denominator, so a hazard or
risk ratio could not be determined. As the main object-
ive of most selected studies was not to determine the
incidents, adverse events or malfunctions associated
with the use of PTCA catheters, it is uncertain that
contacting the principal investigators of the published
studies would have yielded additional insights with
regards to their safety. Furthermore, there was no single
classification system for complications, making it diffi-
cult to compare or aggregate adverse event types and
risk across studies. Although the majority of the adverse
event reports associated with the use of PTCA catheters
submitted to the FDA were related to material rupture
(data not reported), none of the selected studies reported
any device malfunction when used in their clinical setting.
Furthermore, the patient outcomes for 1,662 adverse
event reports submitted to the FDA remained unknown.
This lack of information precludes us from a comparison
analysis between these outcomes and patient outcomes
reported in the selected studies.Another limitation is the lack of standard reporting of
device brands and models. PTCA catheter brands and
models were reported in only four studies [21,23,29,30].
Medical devices do not have an assigned unique identi-
fier. Consequently, it is impossible to identify the spe-
cific device used in a patient if an adverse event occurs
after the fact. Furthermore, none of the retrospective
studies described the registries or existing surveillance
programs in their institutions. Details of the structures
used for data collection, intended use of the data and
subsequent approaches to improve patient care would
offer clarification on PMS in clinical practice. Important
considerations in the development of research method-
ologies to identify the risk of adverse events and device
malfunctions include product lifecycle, the learning
curve of the device operator and the use of a device ex-
ternal to the original indication [35].
RCTs are considered to be the gold standard in the
medical literature. Numerous disadvantages, however,
exist with the sole use of clinical trials to assess the safety
and effectiveness of medical devices. They are as follows:
inadequate sample size to detect rare adverse events, short
follow-up period, reduced generalizability of findings due
to strict exclusion criteria, difficulties with maintaining
blinding and allocation concealment, and high costs asso-
ciated with designing many clinical trials for technologies
that are evolving rapidly [36]. Normand et al. proposed a
framework that combines pre-market and post-market
data to measure the performance of medical devices [36].
To illustrate the proposed methods, a Bayesian hierarch-
ical method was employed to combine clinical scores and
outcomes from three studies using a RCT and observa-
tional designs on hip arthroplasty. The authors concluded
that this method allows the performance data of medical
devices to be monitored throughout the product lifecycle,
increases transparency with explicit assumptions and is in-
dicative of existing evidence gaps [36].
Limitations
Our literature search strategy was limited to the pub-
lished and grey literature of full-text reports available in
the past five years, to determine the impact of the reclas-
sification of PTCA catheters from a class III to class II
risk level by the FDA in 2011 and to identify studies
relevant to current clinical practice. Studies were also re-
stricted to English and French publications due to lim-
ited resources and time restrictions. Although Morrison
et al. found no systematic bias when English-language
restrictions were imposed in systematic reviews, the au-
thors of the current review acknowledge that some bias
may still exist by imposing language restrictions in the
literature search strategy as further research is required
in this area [37]. It is unlikely that we would have found
a sufficient number of studies in other languages to
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ber of reports in the published medical and grey litera-
ture and the number of reports from the FDA as the gap
is significant. In addition, the inclusion criteria were de-
fined by the published and grey literature. According to
the results of the systematic review, it is a challenge to
estimate accurately the extent of adverse events and de-
vice malfunctions associated with the use of PTCA in
patients with CAD based solely on the available pub-
lished and grey literature. As our primary study objective
was to review the PMS studies in the medical and grey
literature published between 2007 and 2012, we did not
contact the authors of the included studies to obtain add-
itional details. The limited information available in some
of these studies is indicative of the inadequate reporting of
PMS associated with the use of PTCA catheters in pa-
tients with CAD in the medical and grey literature. Doshi
et al. suggested that complete and anonymized clinical
study reports would provide supplemental evidence that is
not available in publications, partly due to word limits im-
posed by biomedical journals [38]. For instance, one pub-
lished trial on oseltamivir reported no adverse events,
while the clinical study report listed three that may have
been associated with its use [38]. On the other hand, man-
ufacturers are not required to conduct a clinical trial to
demonstrate the safety and efficacy of a medical device for
pre-market approval.
Directions for future research
Medical devices that pose an increased risk of harm in
patients could be an important indicator for the discon-
tinuation of their use in patients. Our systematic review,
however, illustrates that the volume and quality of PMS
studies associated with the PTCA catheters in patients
with CAD are low in the published and grey literature,
and are not useful sources of information for decisions
on safety. The validity and feasibility of other methods,
such as the use of both published and unpublished data,
that can inform the risk of the use of a medical device
warrant further exploration.
Since clinical trials are not required for medical devices
for pre-market approval, databases and surveillance sys-
tems for reporting adverse events associated with medical
devices may provide some insight that is unavailable in
published studies. Passive surveillance systems, such as
the MAUDE database [39], are considered to underreport
adverse events. Reasons for underreporting include the in-
ability to link an adverse event to a specific device, lack of
awareness of the reporting systems, a lack of an obligation
to report adverse events and concerns with liability issues
[36]. Another concern with surveillance systems is the
challenge in accurately detecting the cause of the adverse
events. Further investigations are required to improve
current surveillance systems. The FDA launched MedSun,a Medical Product Safety Network, in 2002. To date,
trained representatives from over 350 health-care facilities,
report adverse events to MedSun that occurred in their fa-
cility resulting from the use of a medical device [40]. One
challenge that remains is capturing the number of devices
used in practice, which would give a better understanding
of the rate of related adverse events [41]. The comprehen-
siveness of the database and its impact in risk manage-
ment merit further investigation.
New initiatives, such as the Medical Device Epidemi-
ology Network, spearheaded by the FDA Center for De-
vices and Radiologic Health, aim to develop and advance
research methods to improve the accuracy and volume
of evidence on the safety and effectiveness of medical
devices through collaborations with academic institu-
tions. At the time of writing this review, the network
was not fully operational [42], so its impact both on
PMS and in clinical practice cannot be assessed yet. Fu-
ture studies may examine innovative statistical methods
to combine information from diverse data sources and
study designs to assess the safety and effectiveness of
medical devices, such as PTCA catheters, accurately.
Conclusions
Our systematic review included 11 studies on PMS of
PTCA catheters in patients with CAD. The study designs
included single- and multiple-arm prospective and retro-
spective studies, non-blinded RCTs and case–control stud-
ies. Their internal validity was generally low. The reported
in-hospital and long-term adverse events involved coronary
perforations, MACE and mortality. There were limited
reports of adverse events common in clinical practice such
as procedure failures, distal vessel occlusion due to
embolization and puncture site complications. One study
did not observe any device malfunctions, and the proced-
ural complications reported in two studies did not appear
to impact patient care severely. Given the volume of ad-
verse events reported to the FDA since 2008, it is unlikely
that the published and grey literature represent the full
spectrum of device malfunctions and adverse events caused
by the use of PTCA catheters. Future studies may explore
the strengths and limitations of PMS databases adminis-
tered by regulatory authorities. Innovative study designs
and statistical methods to measure the safety and effective-
ness of medical devices require further exploration.
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